Eli Lilly and Company (LLY) Stock Price Prediction
Price target with bull & bear cases · AI-assisted, editorially reviewed · Re-evaluated every trading day
Our AI model’s current price target for LLY is $1,366.05 — 9.1% above the latest price of $1252.00.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Eli Lilly is predicated on the continued, robust sales growth of its incretin franchise, notably Mounjaro and Zepbound, which are expected to maintain strong international market share. Further upside is anticipated from the successful development and commercialization of its next-generation pipeline assets, including oral GLP-1 Orforglipron and the triple-hormone-receptor agonist Retatrutide for obesity, as well as progress in its Alzheimer's franchise with Donanemab. The company's manufacturing scaling efforts are expected to enhance margins, and there is potential for increased guidance following strong earnings.
Bear Case
The bear case highlights several risks, including significant pricing pressures on GLP-1 drugs due to government programs like Medicare Bridge and potential aggressive rebating from competitors. There is also a risk of slowing demand for mature assets such as Verzenio and Trulicity, signaling competitive and mix pressures. A high valuation coupled with potential pipeline failures, regulatory setbacks, or disappointing clinical trial readouts for new drug candidates could lead to a significant re-evaluation of the stock. Intense competition from other pharmaceutical companies developing similar therapies also poses a threat to market share and profitability.
Model-assessed risk level: High
Key Catalysts to Watch
Continued robust demand and sales growth of the incretin franchise (Mounjaro, Zepbound, Foundayo).
Successful advancement and regulatory approvals of next-generation obesity and cardiometabolic pipeline drugs (e.g., Orforglipron, Retatrutide).
Progress in the Alzheimer's franchise with Donanemab.
Upcoming Q3 2026 earnings report on October 29, 2026, with potential for raised guidance.
Positive outcomes from new clinical trial collaborations (e.g., with Prelude Therapeutics for breast cancer drugs).
Improved manufacturing scaling and efficiency to meet high demand for key products.
Technical Backdrop
RSI-14
67.9
50-Day MA
$1179.27
200-Day MA
$1061.43
From 52-Wk High
-2.2%
Full momentum breakdown: Is LLY overbought or oversold?
Model Notes
Eli Lilly and Company is a prominent pharmaceutical company known for its strong growth, primarily driven by its incretin franchise, including diabetes and obesity treatments like Mounjaro and Zepbound. The company boasts a robust product pipeline, with significant potential in areas such as next-generation obesity and cardiometabolic therapies, and Alzheimer's treatments like Donanemab. While analysts generally hold a 'Strong Buy' consensus, the stock carries a high-risk profile due to its elevated valuation, intense market competition, and ongoing pricing pressures.
The technical outlook for LLY is generally bullish, with the stock trading above its 50-day and 200-day moving averages. The Relative Strength Index (RSI) is in neutral-to-buy territory, and the Moving Average Convergence Divergence (MACD) indicates bullish momentum. The stock has recently cleared a key resistance level and is nearing its all-time high, with short-term moving averages forming a bullish alignment.
Current Street Context
October 15, 2026The AI price target of $1,366.05 for Eli Lilly is well-supported by a strong "Buy" consensus from analysts as of October 15, 2026. The median 12-month price target from 30 Wall Street analysts stands at $1,385, with a range from $930 to $1,600, indicating a generally bullish outlook for the pharmaceutical giant. Eli Lilly is set to release its Q3 2026 financial results on October 29, 2026, with analysts anticipating an EPS of $7.89. Key upcoming events include the potential Q1 2027 regulatory filing for its experimental next-generation drug, retatrutide, and the recent April 2026 launch of its oral GLP-1, Foundayo, for obesity. The company maintains a robust pipeline across metabolic disease, neuroscience, oncology, and immunology, demonstrating a high pace of innovation. These targets are estimates and not guarantees.
Frequently Asked Questions
What is the price target for LLY?
How is this forecast generated?
How accurate are stock price predictions?
Will LLY stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews LLY’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Overbought or Oversold?
Updated daily
LLY: Why Is It Moving?
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers